Sotrovimab or Xevudy Market 2026–2035 advancing antiviral therapies

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Sotrovimab Or Xevudy Market By 2030 Starting From Its 2026 Size?

Historically, growth was driven by the urgent authorization of COVID-19 monoclonal antibodies, the significant risk of hospitalization during the early phases of the pandemic, the swift deployment of antibody therapies, governmental procurement of antiviral treatments, and the expansion of infrastructure for infusion-based treatments.

The expansion projected for the forecast period is driven by the development of antibody therapies that are resistant to variants, an increasing emphasis on preparedness for future pandemics, a surge in investment directed at antiviral biologics, the broadened availability of outpatient infusion services, and the incorporation of monoclonal antibodies into standard treatment protocols.

Significant trends anticipated for the forecast period encompass the expanding application of monoclonal antibody treatments, a heightened concentration on the early-stage management of viral infections, the growth in targeted antiviral biologics, an increasing priority on safeguarding high-risk patients, and the intensified creation of therapeutics designed for pandemic response.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

What Primary Drivers Are Shaping The Development Of The Sotrovimab Or Xevudy Market?

An increasing occurrence of COVID-19 infections is projected to fuel the expansion of the sotrovimab or xevudy market in the future. This illness, caused by the SARS-CoV-2 virus, transmits via respiratory droplets and can manifest symptoms ranging from minor fever to serious breathing difficulties. Its transmission can be curtailed through vaccination and proper hygiene measures. The uptick in COVID-19 infections stems from elements like emerging variants, diminishing immunity, relaxed public health mandates, seasonal indoor assemblies, and inconsistent vaccine distribution. Sotrovimab is administered to high-risk COVID-19 individuals to neutralize the virus early, thereby averting critical results such as hospital admission or fatality. For example, data from March 2023, sourced from a report by the Office for National Statistics, a UK government body for official statistics, indicated that approximately 1.9 million people in the UK (representing 2.9% of the population) had reported COVID as of that month. A significant majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% enduring symptoms for over a year and 41% for more than two years. Consequently, the escalating incidence of COVID cases is poised to propel the expansion of the sotrovimab or xevudy market.

Which Segment Categories Define The Sotrovimab Or Xevudy Market?

The sotrovimab or xevudy market covered in this report is segmented –

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End User: Pediatric, Adult, Geriatric

Who Are The Top Companies Competing In The Sotrovimab Or Xevudy Market?

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

Read the full sotrovimab or xevudy market report here:

https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

How Does The Sotrovimab Or Xevudy Market Perform Across Major Global Regions?

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Sotrovimab Or Xevudy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp

Browse Through More Reports Similar to the Global Sotrovimab Or Xevudy Market 2026, By The Business Research Company

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795